Trending

inflammatory diseases

Mylan to market Lupin’s Enbrel biosimilar outside US

Lupin’s biosimilar is under review in EU

X

Mylan to market Lupin’s Enbrel biosimilar outside US

https://pharmaphorum.com/news/mylan-to-market-lupins-enbrel-biosimilar-outside-us/

FDA rejects Teva/Celltrion biosimilars

FDA rejects Teva/Celltrion biosimilars

Regulator cites issues with manufacturing plant

X

FDA rejects Teva/Celltrion biosimilars

https://pharmaphorum.com/news/fda-rejects-teva-celltrion-biosimilars/

Biogen gets go-ahead for EU Humira launch in October

Biogen gets go-ahead for EU Humira launch in October

But deal with Samsung prevents US launch until mid-2023

X

Biogen gets go-ahead for EU Humira launch in October

https://pharmaphorum.com/sales-marketing/biogen-gets-go-ahead-eu-humira-launch-october/

Celgene’s COO quits after troubles with new drugs

Celgene’s COO quits after troubles with new drugs

Celgene’s chief operating officer and inflammatory diseases guru Scott Smith has quit the company, in the aftermath of

X

Celgene’s COO quits after troubles with new drugs

https://pharmaphorum.com/oncology/celgenes-coo-quits-troubles-new-drugs/

Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisers

Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisers

Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few

X

Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisers

https://pharmaphorum.com/news/pfizer-eyes-gastro-use-xeljanz-thumbs-fda-advisers/

Celgene to tackle ‘undruggable’ targets with Vividion

Celgene has signed a deal with Vividion Therapeutics to develop drugs for oncology, inflammatory, and neurodegenerative diseases.

X

Celgene to tackle ‘undruggable’ targets with Vividion

https://pharmaphorum.com/news/celgene-to-tackle-undruggable-targets-with-vividion/

Lilly aims for new indication for Taltz

Lilly aims for new indication for Taltz

Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and

X

Lilly aims for new indication for Taltz

https://pharmaphorum.com/news/eli-lilly-aims-new-indication-il-17-drug-taltz/

Pfizer’s rituximab biosimilar gets late-stage trial boost

Pfizer’s rituximab biosimilar gets late-stage trial boost

Phase 3 success sets up showdown with Roche, Sandoz, and Celltrion

X

Pfizer’s rituximab biosimilar gets late-stage trial boost

https://pharmaphorum.com/news/pfizers-rituximab-biosimilar-succeeds-phase-3-trial/

Novartis files Humira biosimilar in US

Novartis files Humira biosimilar in US

Novartis’ Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of

X

Novartis files Humira biosimilar in US

https://pharmaphorum.com/news/sandoz-files-humira-biosimilar-us/

1 2 3 4

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com